Narcotics Analgesics Market size is projected to surpass USD 51 Billion by the end of 2035, growing at a CAGR of 5% during the forecast period i.e., 2023-2035. In the year 2022, the industry size of narcotics analgesics was over USD 27 Billion.The growth of the market can be attributed to the rise in the research and development of narcotics analgesics worldwide. Further, the increased use of heroin, a type of narcotic analgesic, is also expected to contribute to market growth. In 2019, more than 40,000 people tried heroin for the first time and in 2020, around 7,00,000 people used heroin. Besides this, the rise in concern for the misuse of pain killers and the myth that pure heroin is less harmful than less pure heroin forms is also poised to create numerous opportunities for market growth in the coming years. Also, a growing tolerance to non-narcotics analgesics is the major reason for the constant increase in sales of narcotics analgesics.
In addition to these, factors that are believed to fuel the market growth of narcotics analgesics include the quick onset of action of these pharmaceutical drugs and the high efficiency of these drugs for neuropathic pain management. In addition to this, the rise in demand for drugs for pain relief related to the central nervous system (CNS), such as morphine, is also anticipated to drive market growth. International Narcotics Control Board reported that 79% of the world’s population consumed 13% of morphine used for the management of pain and suffering or 1% out of 388.2 tons of total morphine manufactured across the world.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~5% |
|
Base Year Market Size (2022) |
~ USD 27 Billion |
|
Forecast Year Market Size (2035) |
~ USD 51 Billion |
|
Regional Scope |
|
Administration Route (Oral, Intravenous, Rectal, Transdermal, Topical)
The global narcotics analgesics market is segmented and analyzed for demand and supply by administration route into oral, intravenous, rectal, transdermal, and topical. Out of the five types of administration routes, the oral segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the simple administration through the oral route, the non-invasive nature of administration, and the increased efficiency of these drugs when compared to other routes of administration. Over 80% of drugs in high demand are oral route products with a value of USD 30 billion and a growth rate of 10% annually.
Application (Pain Management, Cough Treatment, Diarrhea)
The global narcotics analgesics market is also segmented and analyzed for demand and supply by application into pain management, cough treatment, and diarrhea. Amongst these three segments, the pain management segment is expected to garner a significant share by the end of 2035. Narcotics analgesics are highly used to relieve pain killer, these drugs can be really effective in reducing the pain in the patients suffering from cancer and cardiovascular issues. Therefore, the rising cases of cancer and heart patients is expected to boost the segment growth. According to the World Cancer Research Fund International in 2020, there were 18.1 million new cases of cancer worldwide. 9.3 million of these instances involved men, while 8.8 million involved women. Furthermore, one in fourteen persons worldwide suffers from a heart or circulatory illness. Moreover, according to current estimates, there are around 290 million women and nearly 260 million men suffering from heart and circulation illnesses worldwide.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By Administration Route |
|
North American Market Forecast
The North American narcotics analgesics market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increased consumption of opioids for both medical and non-medical purposes. Over 80% of the world's opioids are consumed in the United States, which has 4.4% of the world's population. About 99% of the hydrocodone used worldwide is used in the US. Moreover, between 2015-2018 about 10.7% of U.S adults aged 20 and above used one or more prescription pain medications (opioid or nonopioid) and 5.7% used one or more prescription opioids, as per the statistics by the Centers for Disease Control and Prevention (CDC). Furthermore, rising cases of arthritis and osteoarthritis in the region are also expected to augment the market growth in the region. In 2020, every 1 in 4 adults in the United States are suffering from arthritis, further, it is estimated around 27 million adults in the region are likely to have arthritis by 2040. In addition to this, the most prevalent joint condition in the US is osteoarthritis. More than 33 million American people will have osteoarthritis by 2020.
Johnson & Johnson Services, Inc. announced a settlement agreement with the State of New York and its subdivisions, resolving their opioid-related claims against the Company. The settlement will provide about USD 263 million in funding for New York and its subdivisions to address opioid-related issues and as reimbursement for attorney fees and costs.
AbbVie Inc. in association with Neurocrine Biosciences, Inc. announced the release of first and only gonadotropin-releasing hormone ORILISSA that has been approved by the U.S Food and Drug Administration.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?